RxDoctor Payments Data

Andrew Persits, MD

Interventional Cardiology · Riverhead, NYNPI 1457678179

Payments from drug & device makers

$5,915in general payments, 2019–2025

Across 85 payments — averaging $69.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$1K
  • Abiomed$772
  • Edwards Lifesciences$346
  • Novartis$210
  • Shockwave Medical, Inc$196
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$60010%
  • Food & beverage$5,31590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,915 in reported general payments places this provider in the 35th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$267,775
Medicare patients
732
Services billed
2,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban201$253,812
XareltoRivaroxaban85$116,080
EntrestoSacubitril/Valsartan80$109,322
JardianceEmpagliflozin17$27,393
FarxigaDapagliflozin Propanediol14$23,559
Repatha SureclickEvolocumab17$19,050
BrilintaTicagrelor12$10,529
Metoprolol Succinate403$6,278
Atorvastatin Calcium329$3,484
Rosuvastatin Calcium200$3,226
Losartan Potassium250$2,586
ClopidogrelClopidogrel Bisulfate105$1,466
Amiodarone Hcl21$1,408
Amlodipine Besylate178$1,191
Torsemide27$1,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$146$116,08085 claims
NovartisEntresto$210$109,32280 claims
Boehringer IngelheimJardiance$125$27,39317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Riverhead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →